This finding shows the importance of CD28 targeting in agreement with the observations of Wu et al. [24] and is consistent with tumor immune escape to TC engager treatments, caused by not only the loss of target antigen but also the proportion of pre-existing exhausted-like CD8+ TCs [7]. This evidence concerns the gene CD8A and neoplasm.